Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2020 | Biomarker blood tests as diagnostic tool for Alzheimer’s disease

Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, discusses the progress for a diagnostic blood test for Alzheimer’s disease. Results have shown that plasma amyloid-β 42/40 ratio is highly concordant to the amyloid PET scan. Further, plasma p-tau is also concordant to the amyloid PET scan and is predictive of the severity of dementia- which the amyloid-β 42/40 ratio cannot predict. Dr Schindler concludes that further research should be executed on the combination of both biomarkers. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).